Johan Lundberg's research group
Molecular imaging, neuropsychopharmacology, mood and anxiety disorders
The overriding aim of our research is to improve the treatment of major psychiatric disorders. Our main activity involves in vivo and post mortem molecular imaging to study the pathophysiology and pharmacology of mood and anxiety disorders, and to some extent autism spectrum disorders.
One vision of the group is to develop imaging markers for antidepressant treatment response. To this end, we study the molecular effect in man in vivo of different antidepressant treatments, such as Cognitive Behavioral Treatment, antidepressant drug treatment, Electro Convulsive Treatment and novel antidepressant treatments such as ketamine. We have had a focus on the serotonin system, but are performing studies also on the GABA and Glutamate systems. The development of molecular imaging analysis and statistics is an integrated part of our work.
Our work is supported by the Swedish Science Council, the Stockholm County, the Söderström-Königska foundation and from a generous private donation.
UR Samtiden Hjärndagen 2019 - Depression-en sjukdom och dess behandling
A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression.
Tiger M, Veldman ER, Ekman CJ, Halldin C, Svenningsson P, Lundberg J
Transl Psychiatry 2020 06;10(1):159
Serotonin transporter availability in adults with autism-a positron emission tomography study.
Andersson M, Tangen Ä, Farde L, Bölte S, Halldin C, Borg J, et al
Mol. Psychiatry 2020 Aug;():
Validity and reliability of extrastriatal [11C]raclopride binding quantification in the living human brain.
Svensson JE, Schain M, Plavén-Sigray P, Cervenka S, Tiger M, Nord M, et al
Neuroimage 2019 Nov;202():116143
GABAA receptor availability is not altered in adults with autism spectrum disorder or in mouse models.
Horder J, Andersson M, Mendez MA, Singh N, Tangen Ä, Lundberg J, et al
Sci Transl Med 2018 10;10(461):
Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2.
Arakawa R, Stenkrona P, Takano A, Svensson J, Andersson M, Nag S, et al
Int. J. Neuropsychopharmacol. 2019 04;22(4):278-285
A [11 C]raclopride positron emission tomography study of dopamine-D2/3 receptor binding in patients with severe major depressive episodes before and after electroconvulsive therapy and compared to control subjects.
Tiger M, Svensson J, Liberg B, Saijo T, Schain M, Halldin C, et al
Psychiatry Clin. Neurosci. 2020 Jan;():
Distribution and levels of 5-HT1B receptors in anterior cingulate cortex of patients with bipolar disorder, major depressive disorder and schizophrenia - An autoradiography study.
Veldman ER, Svedberg MM, Svenningsson P, Lundberg J
Eur Neuropsychopharmacol 2017 05;27(5):504-514
Reduced 5-HT(1B) receptor binding in the dorsal brain stem after cognitive behavioural therapy of major depressive disorder.
Tiger M, Rück C, Forsberg A, Varrone A, Lindefors N, Halldin C, et al
Psychiatry Res 2014 Aug;223(2):164-70
5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects.
Stenkrona P, Halldin C, Lundberg J
Eur Neuropsychopharmacol 2013 Oct;23(10):1190-8
Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder.
Lundberg J, Tiger M, Landén M, Halldin C, Farde L
Int. J. Neuropsychopharmacol. 2012 Sep;15(8):1167-72
Quantification of 11C-MADAM binding to the serotonin transporter in the human brain.
Lundberg J, Odano I, Olsson H, Halldin C, Farde L
J. Nucl. Med. 2005 Sep;46(9):1505-15
Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET.
Jovanovic H, Lundberg J, Karlsson P, Cerin A, Saijo T, Varrone A, et al
Neuroimage 2008 Feb;39(3):1408-19